Health ❯Healthcare ❯Clinical Trials

Drug Efficacy

Side Effects Patient Outcomes Comparative Studies Lenacapavir Combination Therapy Semaglutide Trials Lecanemab Weight Loss Trials Wegovy Trials Weight Loss Outcomes Lecanemab Trials Baxdrostat Novo Nordisk Cognitive Decline Weight Loss Drugs Leqembi Real-World Evidence Amycretin Amycretin Studies Obesity Treatments Patient Safety Zepbound Semaglutide Study Alzheimer's Treatment Ivermectin Mounjaro Trials Capivasertib Trials Gonorrhea Treatment Orforglipron Study Results Semaglutide Palivizumab Zenith Trial Ubrogepant Weight-loss Injections Statin Therapy Early Stage Trials Sub-Saharan Africa Cognitive Impairment Pain Relief Mechanisms Amycretin Trials EMPACT-MI Trial Weight Loss Studies Alyftrek Results Ivonescimab Alzheimer's Treatments Placebo-Controlled Trials Weight Regain Studies Cardiovascular Protection Teplizumab Trials Mifepristone Complications Eli Lilly Enfortumab Vedotin and Pembrolizumab Elamipretide Semaglutide and Tirzepatide Obicetrapib Wegovy Study Results Pre-exposure Prophylaxis (PrEP) GLP-1 Receptor Agonists Lecanemab and Donanemab Weight Loss Medications Tirzepatide Study Long-term Effects SGLT-2 Inhibitors Vutrisiran COVID-19 Studies Phase Three Trials Pembrolizumab Kisunla Nirsevimab Trials Donanemab

France Blocks Early Access to Alzheimer’s Drug Leqembi for Now

The health regulator says the trial benefit is too small to justify early availability.

Kennedy Alleges Biden Team Skewed Abortion-Pill Data as FDA Review of Mifepristone Proceeds

FDA Clears At-Home Leqembi Injection for Weekly Maintenance in Early Alzheimer’s

Baxdrostat Lowers Blood Pressure in Hard-to-Treat Patients in Phase III Trial

NICE Recommends Padcev–Keytruda as First-Line NHS Treatment for Advanced Bladder Cancer

Paclitaxel Reengineered Into Self-Assembling Nanovesicle Shows Strong Preclinical Gains

MHRA Licenses Teplizumab to Delay Onset of Type 1 Diabetes

Eli Lilly’s Oral Obesity Pill Triggers Stock Slide After Modest Weight-Loss Results

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

NHS to Deploy Single-Dose RSV Antibody Jab for 7,000 Preterm and High-Risk Infants

NICE Approves Alyftrek, Extending Modulator Treatment to 95% of Cystic Fibrosis Patients

Nature Study Shows Gut Bacterium YB328 Boosts Cancer Immunotherapy

Novo Nordisk’s Amycretin Delivers Up to 24% Early Weight Loss in Dual-Form Trials

FDA Approves Yeztugo, Gilead’s Twice-Yearly HIV Prevention Injection

NICE Bars New Alzheimer’s Antibodies from NHS Over Cost and Capacity

Statins Linked to 39% Drop in 28-Day Mortality for Sepsis Patients

Sotatercept cuts risk of death and hospitalization by 76% in advanced pulmonary arterial hypertension

Australia Approves Donanemab as First Disease-Modifying Alzheimer’s Therapy